Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Aggressive New HIV Strain Leads to AIDS Faster

By LabMedica International staff writers
Posted on 11 Dec 2013
A new aggressive strain of human immunodeficiency virus (HIV) develops more rapidly into acquired immunodeficiency syndrome (AIDS) than other current strains.

Human immunodeficiency virus type 1 (HIV-1) is characterized by a high genetic diversity, a consequence of an extremely high replication rate, an error-prone reverse transcriptase, recombination events during replication, and host selective immune pressure. More...
HIV-1 is divided into subtypes and the impact circulating recombinant forms (CRFs) need to be investigated.

Scientists at the Lund University (Sweden) analyzed blood samples obtained from individuals enrolled in a cohort comprising police officers in Guinea-Bissau. The cohort includes 225 HIV-1 seroincident individuals with estimated dates of seroconversion, defined as the midpoint between the last seronegative and the first seropositive sample. In total, samples were available for 191 individuals.

Viral ribonucleic acid (RNA) was extracted from blood plasma samples amplified by reverse-transcription polymerase chain reaction, and the C2–V3 region (460 bp) sequenced. Clones were amplified using Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA, USA) and conventional M13 primers (−20 and −24) and sequenced using primers JA170, JA169 or M13 reverse primer.

The major subtypes/CRFs identified were CRF02_AG (53%), A3 (29%), and A3/02 (a recombinant of A3 and CRF02_AG) (13%). Infection with A3/02 was associated with a close to three-fold increased risk of AIDS and AIDS-related death compared to A3, respectively. The estimated time from seroconversion to AIDS and AIDS-related death was 5 and 8 years for A3/02, 6 and 9 years for CRF02_AG, and 7 and 11 years for A3.

Patrik Medstrand, PhD, professor of Clinical Virology at Lund University, said, “HIV is an extremely dynamic and variable virus. New subtypes and recombinant forms of HIV-1 have been introduced to our part of the world, and it is highly likely that there are a large number of circulating recombinants of which we know little or nothing. We therefore need to be aware of how the HIV-1 epidemic changes over time.” The study was published in the November 2103 issue of the Journal of Infectious Diseases.

Related Links:

Lund University
Invitrogen 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.